Trial Profile
A Randomized, Double-blind, Comparator-controlled Trial to Assess the Effect of 12-week Treatment With Dapagliflozin Versus Gliclazide on Renal Physiology and Biomarkers in Metformin-treated Patients With Type 2 Diabetes Mellitus
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 24 May 2022
Price :
$35
*
At a glance
- Drugs Dapagliflozin (Primary) ; Gliclazide
- Indications Type 2 diabetes mellitus
- Focus Pharmacodynamics
- Acronyms RED
- 01 May 2022 Results of two studies (NCT02682563 & NCT05210517) assessing mechanisms of plasma uric acid lowering by SGLT2 inhibitors in people with type 2 diabetes with a focus on urate transporter 1, published in the Clinical Journal of The American Society of Nephrology: CJASN.
- 15 Oct 2018 Status changed from recruiting to completed.
- 19 May 2017 Planned End Date changed from 1 May 2018 to 1 Oct 2018.